Square Pharmaceuticals PLC.

DSE:SQURPHARMA Voorraadrapport

Marktkapitalisatie: ৳193.8b

Square Pharmaceuticals Toekomstige groei

Future criteriumcontroles 1/6

Square Pharmaceuticals is forecast to grow earnings and revenue by 12.6% and 9% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be 19.2% in 3 years.

Belangrijke informatie

12.6%

Groei van de winst

13.5%

Groei van de winst per aandeel

Pharmaceuticals winstgroei17.1%
Inkomstengroei9.0%
Toekomstig rendement op eigen vermogen19.2%
Dekking van analisten

Low

Laatst bijgewerkt19 Sep 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DSE:SQURPHARMA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (BDT Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
6/30/202792,80532,14725,61321,8091
6/30/202685,23328,22024,92323,5272
6/30/202577,31823,90218,62819,2432
6/30/202470,46521,27618,44515,8253
3/31/202468,81120,23810,33914,192N/A
12/31/202367,46919,59912,08813,911N/A
9/30/202365,13719,4809,62011,800N/A
6/30/202362,74818,9805,7218,546N/A
3/31/202362,02018,8566,96810,289N/A
12/31/202260,78219,1436,25210,594N/A
9/30/202258,79118,6806,85912,222N/A
6/30/202257,59818,1576,69212,875N/A
3/31/202256,71318,5268,51414,936N/A
12/31/202154,83417,8198,30714,183N/A
9/30/202153,00417,0129,07013,949N/A
6/30/202150,70315,9477,17810,976N/A
3/31/202149,02114,4847,34410,544N/A
12/31/202048,39514,2379,53212,249N/A
9/30/202047,15813,9337,90310,427N/A
6/30/202045,87613,3548,71810,760N/A
3/31/202046,36013,73310,20312,019N/A
12/31/201945,13813,2369,78011,586N/A
9/30/201944,78512,83110,78012,455N/A
6/30/201944,03412,64610,34312,392N/A
3/31/201942,32212,1688,10110,525N/A
12/31/201841,25212,0256,6459,288N/A
9/30/201840,32811,7546,2769,493N/A
6/30/201839,65411,5946,7389,905N/A
3/31/201839,47411,6675,7779,371N/A
12/31/201739,13111,622N/A10,071N/A
9/30/201737,97811,222N/A9,723N/A
6/30/201736,54310,637N/A9,542N/A
3/31/201735,58410,330N/A9,806N/A
12/31/201634,5349,893N/A9,348N/A
9/30/201633,4489,639N/A10,637N/A
6/30/201633,0749,199N/A9,615N/A
12/31/201529,6427,770N/A9,487N/A
9/30/201528,4007,091N/A8,298N/A
6/30/201527,5316,411N/A7,223N/A
3/31/201525,9796,032N/A6,246N/A
12/31/201425,8585,060N/A5,586N/A
9/30/201425,5115,122N/A5,763N/A
6/30/201424,1765,002N/A5,513N/A
3/31/201423,2684,945N/A6,416N/A
12/31/201323,0184,988N/A7,217N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: SQURPHARMA's forecast earnings growth (12.6% per year) is above the savings rate (3.7%).

Winst versus markt: SQURPHARMA's earnings (12.6% per year) are forecast to grow slower than the BD market (17.3% per year).

Hoge groeiwinsten: SQURPHARMA's earnings are forecast to grow, but not significantly.

Omzet versus markt: SQURPHARMA's revenue (9% per year) is forecast to grow slower than the BD market (9.3% per year).

Hoge groei-inkomsten: SQURPHARMA's revenue (9% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: SQURPHARMA's Return on Equity is forecast to be low in 3 years time (19.2%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y